| Similar Articles |
|---|
 |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.   |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
October 10, 2003
Jeffrey Skolnick |
Protein Structure Prediction in Drug Discovery Indications are that structure prediction can assist in the automated assignment of proteins to known pathways. |
Bio-IT World
June 12, 2002
Mark D. Uehling |
Putting Proteins in Their Place Will a 'periodic table' of proteins help classify the ungainly beasts? |
Bio-IT World
February 2007
Varmazis & Davies |
Expanding Galapagos Lands Inpharmatica The recent acquisition by Galapagos of U.K.-based informatics company Inpharmatica puts the Belgian drug discovery company in a healthy position to compete in the competitive service provider segment for the biopharma industry. |
Bio-IT World
September 11, 2003
Mark D. Uehling |
Fishing Chips The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may threaten the early leads of Biacore and Ciphergen -- and work so well that drug companies won't want them. |
Bio-IT World
August 15, 2005 |
News Blast Computational drug discovery solutions provider Eidogen-Sertanty launched a chemist-friendly design service... Thomson Scientific providing an XML gateway to its collection of publications... Inpharmatica launched a modular protein annotation system... etc. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
